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Objective: Atherosclerosis preferentially develops at sites of disturbed blood ﬂow. We tested the
hypothesis that transglutaminase activity plays a role in plaque development at these locations.
Methods and results: Exposure of endothelial cells to steady ﬂow (7 dynes/cm2) was associatedwith relatively
low transglutaminase activity, whereas under low oscillatory ﬂow (1.3  2.6 dynes/cm2) endothelial cells
showed a >4-fold higher level of transglutaminase activity. Under oscillatory ﬂow, transglutaminase activity
increased the expression of the chemokineMCP-1 (CCL2). In vivo, oscillatory ﬂowwas induced by placement of
a tapered perivascular cast around the carotid artery of type 2 transglutaminase (TGM2) knockoutmice andWT
counterparts. After 2 days, signiﬁcantly lessmonocytes adhered to the endothelium in TGM2 knockoutmice as
compared toWT. In a more chronic setting, ApoE knockout mice that were equipped with the ﬂow-modifying
cast developed lesions proximal to the cast (low shear stress), and distal to the cast (oscillatory shear stress).
Inhibition of transglutaminase induced amarked reduction inmacrophage and fat content in distal lesions only.
In addition, lesion sizewas increased in this area,whichwas attributed to an increase in smoothmuscle content.
Conclusion: Oscillatory shear stress increases endothelial transglutaminase activity. In turn, trans-
glutaminase activity affects the expression of MCP-1 in vitro and monocyte recruitment in vivo. In
a mouse model of atherosclerosis, transglutaminase activity has a major effect on plaque composition
under oscillatory shear stress.
 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Atherosclerosis is a multi-factorial disease involving genetic
factors, life-style, and local hemodynamic conditions. Lesions
develop preferably in large vessels at bifurcations, curvatures and
side branches [1]. Here, endothelial cells are exposed to oscillatory
and low shear stress. This hemodynamic proﬁle affects the local
coagulation state, increases the expression of leukocyte adhesion
factors, and promotes the formation of reactive oxygen species
[2e4]. These conditions may promote the inﬁltration of leukocytes,
a key step in the initiation of atherosclerosis.
Transglutaminases are enzymes with a broad spectrum of
actions, including cell signaling and protein cross-linking, by
formation of a g-glutamyl-ε-lysine cross-link [5]. Transglutaminaseþ31 20 6917233.
kker).
der the Elsevier OA license.type 2 (TGM2 or tTG) is highly expressed in endothelial cells, and
accumulating evidence suggests a role for TGM2 in processes
thought to be relevant for initiation and progression of athero-
sclerosis. Thus, endothelial expression of TGM2 is increased by
turbulent shear stress [6], downregulated by high shear stress [7],
and increased after exposure to inﬂammatory cytokines [8,9].
TGM2 is present at endothelial cellecell and cell-matrix contact
points [10], and inhibition of TGM2 leads to reduced cell spreading
and attachment [11]. Activation of TGM2 in endothelial cells by
auto-antibodies against TGM2 from patients with celiac disease
was found to increase permeability and leukocyte transmigration
[12]. We previously found that inhibition of transglutaminase
activity reduces the inﬁltration ofmacrophages in amodel based on
a non-ﬂow limiting cuff placed around the femoral artery in ApoE3
Leiden mice on high fat diet [13]. Based on these ﬁndings, we
hypothesized that TGM2 activity is critically involved in plaque
development under disturbed ﬂow. Indeed, in the present study we
Fig. 1. Transglutaminase activity is regulated by shear stress. A) Confocal microscopic images to detect FITC-cadaverine incorporation in HUVECs as a measure of transglutaminase
activity. Cells were cultured under static conditions or exposed for 24 h to either laminar shear stress at 1.3 dyne/cm2, 7 dyne/cm2 or oscillatory shear stress at 1.3  2.6 dyne/cm2.
Scale bar ¼ 50 mm. B) Quantiﬁcation of FITC-cadaverine incorporation in endothelial cells exposed to 0, 1.3, 7 and 1.3  2.6 dyne/cm2 respectively (n ¼ 5 each). Data are normalized
to the number of cells and to the respective static counterparts. C) TGM2 mRNA levels in HUVECs cultured under shear stress levels of 0, 1.3, 7 and 1.3  2.6 dyne/cm2 respectively
(n ¼ 4 each). Data are normalized to the housekeeping gene, ribosomal protein P0. D) TGM2 protein levels in HUVECs cultured under shear stress levels of 0, 1.3, 7 and
1.3  2.6 dyne/cm2 respectively (n ¼ 2e4). Data are normalized to tubulin expression as reference protein. *Indicates p < 0.05, **p < 0.01, and ***p < 0.001.
H.L. Matlung et al. / Atherosclerosis 224 (2012) 355e362356show that endothelial TGM2 is an important regulator of leukocyte
inﬁltration, plaque size and plaque composition in areas exposed to
oscillatory shear stress.
2. Methods
An expanded description is available in the supplemental data.
2.1. In vitro ﬂow setup and endothelial cell culture
HUVECs were cultured in Ibidi ﬂow chambers and exposed to
different ﬂow conditions for 24 h: static, steady low ﬂow (1 ml/min), normal ﬂow (5.4 ml/min) or oscillatory low ﬂow (1 ml/
min  2 ml/min) leading to shear stress levels of 0, 1.3, 7 and
1.3  2.6 dyne/cm2 respectively. Transglutaminase activity was
determined using the ﬂuorescent substrate FITC-cadaverine.2.2. In vivo mouse model of disturbed blood ﬂow
Female TGM2 knockout mice and wild type (WT) counterparts
(n¼ 5 each) were equipped with a tapered polymethylpentene cast
(diameter 200e400 mm, 1.5 mm length) around the carotid artery
[14]. This tapered cast creates different shear stress regions, i.e.
lowered shear stress proximal of the cast, an increased shear stress
H.L. Matlung et al. / Atherosclerosis 224 (2012) 355e362 357region inside the cast and an oscillatory shear stress region distal
from the cast [15].
2.3. Mouse model of atherosclerosis
Amouse model of atherosclerosis based on the perivascular cast
was used to investigate the effect of transglutaminase inhibition on
plaque development [14]. Female ApoE/ (n ¼ 16) mice were fed
a Western type diet containing 0.25% cholesterol. In eight mice, in
addition to the cast, an osmotic minipump (Alzet, model 1004) was
placed in the intraperitoneal cavity containing the trans-
glutaminase inhibitor L682777. Velocity and diameter measure-
ments were performed using a Vevo 770 system (Visualsonics) and
a 40 MHz probe (RMV-704). After sacriﬁce, sections of carotid
arteries were stained with Oil Red O to determine fat-deposits, and
antibodies against CD68 and 1A4 to identify macrophages and
smooth muscle cells respectively.
3. Results
3.1. Oscillatory shear stress increases transglutaminase activity in
endothelial cells
To investigate the effect of shear stress proﬁles on trans-
glutaminase activity in endothelial cells, HUVECs were cultured
under static, steady, or oscillatory ﬂow proﬁles for 24 h in the
presence of the ﬂuorescent substrate FITC-cadaverine. A clear
difference in transglutaminase activity was found between steady
shear stress at a level of 7 dynes/cm2 as compared to oscillatory
shear stress, which appeared to induce the highest level of trans-
glutaminase activity (Fig. 1A and B). Usually, a granular staining
pattern of transglutaminase activity was found, with sometimes an




































Fig. 2. Transglutaminase regulates MCP-1 expression under oscillatory shear stress effect of t
C) ICAM-1 and D) VCAM-1 in HUVECs exposed to oscillatory shear stress. Transglutaminase
each). Data are normalized to the housekeeping gene, ribosomal protein P0. *Indicates p <levels of TGM2 mRNA were substantially decreased in all groups
exposed to ﬂow as compared to static, with no apparent differences
between shear stress patterns (Fig. 1C). The effect of ﬂow on TGM2
mRNA levels was reﬂected in protein levels, albeit to a lesser extent.
Thus, western blot analysis showed that protein levels decreased in
all groups exposed to ﬂow, which reached statistical signiﬁcance for
the highest steady ﬂow group and the oscillatory ﬂow.
3.2. Inhibition of TGM2 decreases the expression of MCP-1 under
oscillatory shear stress
Oscillatory shear stress is often reported to promote a pro-
inﬂammatory state of the endothelium. To study the relevance of
the relatively high transglutaminase activity in this context, we
studied the expression of MCP-1, ICAM-1, VCAM-1 and E-selectin
under oscillatory shear. We found that when HUVECs exposed to
oscillatory shear were incubated with the transglutaminase
inhibitor L682777, the expression of MCP-1 was signiﬁcantly
decreased, to less than 25% of the control level. E-selectin, ICAM-1,
and VCAM-1 expression was not signiﬁcantly changed (Fig. 2). In
comparison to laminar shear stress (7 dynes/cm2), oscillatory shear
did not signiﬁcantly affect the expression of MCP-1, ICAM-1, or
E-selectin (data not shown).
3.3. TGM2 knockout mice show reduced monocyte/macrophage
recruitment
Since we found that transglutaminase activity is increased by
oscillatory shear stress and affects the expression of MCP-1, we
reasoned that this could affect monocyte recruitment. Therefore,
in vivo experiments were done on the carotid artery using a tapered
perivascular cast. This ﬂow-modifying cast induces oscillatory
































ransglutaminase inhibition (TG inhibitor) on mRNA expression of A) MCP-1, B) VCAM-1,
inhibition induced a signiﬁcant decrease in the expression of MCP-1 (P < 0.05, n ¼ 5
0.05.
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mice and WT counterparts. After 2 days, an en face staining of the
endothelium for CD68 positive cells was performed. Monocytes/
macrophages were counted in the area exposed to oscillatory shear
stress. TGM2 knockout mice showed signiﬁcantly less CD68 posi-
tive cells (Fig. 3A and B). The other areas, both proximal to the cast
and within the cast, were devoid of CD68 positive cells.3.4. Mouse model of atherosclerosis
Subsequent experiments were aimed to test the relevance of
transglutaminase activity in a setting of atherosclerosis induced by
altered shear stress. For this purpose, the constrictive cast was
placed around the carotid artery of ApoE/ mice that were fed
a high fat diet. In this model, atherosclerotic lesions are induced by
low shear stress and oscillatory shear stress patterns before and
after the cast respectively. To study the expression of TGM2 in this
model, sections of carotid arteries of ApoE/ mice were stained.
Supplemental Fig. 1 shows that TGM2 staining co-localizes with
endothelial cells, which both cover the lesion as well as the unaf-
fected part of the vessel wall. Staining was also present in smooth
muscle cells, particularly towards the lumen of the vessel. Weak
staining was also observed in the lesion, possibly related to inﬁl-
trating macrophages. To test the role of transglutaminase activity,
eight mice additionally received the transglutaminase inhibitor
L682777, delivered continuously by an osmotic minipump. After
the experimental period of four weeks, no differences were found
in body weight of the control mice and mice receiving the inhibitor
(see Supplemental Table 1). Cholesterol levels as well as triglycerideFig. 3. Adhering monocytes/macrophages in the carotid artery lumen of TGM2 knockout mi
the endothelium. Endothelial cell nuclei are shown by Dapi staining (blue). B) Quantiﬁcation
(n ¼ 5) showed signiﬁcantly less adhering monocytes/macrophages as compared to WT colevels in plasma were also not signiﬁcantly different between
control mice and TG inhibitor treated mice.3.5. Transglutaminase inhibition affects lesion size and composition
in the oscillatory shear stress region
Atherosclerotic lesion development was analyzed hemody-
namically and histologically four weeks after cast placement. The
combination of cast placement and lesion growth resulted in
a similar ﬂow reduction in control mice and mice that received the
transglutaminase inhibitor (control: 58  4%, inhibitor: 58  7%
lower than contralateral ﬂow, Supplemental Table 1). Irrespective
of the presence of the inhibitor, plaques in the low shear stress
region were much larger as compared to lesions in the oscillatory
shear stress regions (p < 0.01, see Fig. 4). When comparing plaque
sizes in the low shear stress region, transglutaminase inhibition did
not signiﬁcantly inﬂuence the atherosclerotic lesion size
(88.5  8.1 103 mm2 in control mice versus 96.9  12.9  103 mm2
in mice receiving the transglutaminase inhibitor, p ¼ 0.6, Fig. 4A
and B). In the oscillatory shear stress region however, trans-
glutaminase inhibition resulted in larger lesions
(12.7  1.3  103 mm2 in control mice and 24.1  3.7  103 mm2 in
transglutaminase inhibitor mice, p ¼ 0.01, Fig. 4A and B).
In the low shear stress region, vessels showed outward
remodeling associated with lesion development (Supplemental
Table 1). This Glagov [16] remodeling is believed to preserve
lumen diameter in the face of a growing plaque. Transglutaminase
inhibition did not inﬂuence this remodeling. The oscillatory shearce and WT counterparts. A) En face staining for CD68 positive cells (green) adhering to
of the number of CD68 positive cells per ﬁeld of view (0.14 mm2). TGM2 knockout mice
ntrols (n ¼ 5). **Indicates (p < 0.01).
AB
Fig. 4. Lesion size and role of transglutaminase depend on localization. A) Plaque area of
control mice (n ¼ 8) and mice receiving the transglutaminase inhibitor (n ¼ 8) at several
locations proximal and distal from the cast. B) Quantiﬁcation of plaque areas based on
sections with the largest lesion in low and oscillatory shear stress regions. Trans-
glutaminase inhibition leads to larger lesions in the oscillatory shear stress region.
* Indicates p < 0.05; ** Indicates p < 0.01. N.s. ¼ not signiﬁcant.
H.L. Matlung et al. / Atherosclerosis 224 (2012) 355e362 359stress region did not show a signiﬁcant increase in vessel diameter,
both with and without the transglutaminase inhibitor.
Plaque composition was analyzed by staining cross-sections of
the atherosclerotic carotid arteries for lipid content by Oil Red O
(Fig. 5A and B). Lesions in the low shear stress region contained
more lipid as detected by Oil Red O staining compared with the
oscillatory shear stress region. After transglutaminase inhibition,
atherosclerotic lesions in the oscillatory shear stress region con-
tained markedly less lipids compared with control mice. In
contrast, the transglutaminase inhibitor did not affect lipid content
in the low shear stress area. High magniﬁcation images of the
oscillatory shear stress region are shown in Supplemental Fig. 2.
Macrophages were detected by staining cross-sections for CD68
(Fig. 5C and D). No signiﬁcant difference in macrophage content
was detected between lesions developed in the low shear stress
region, as compared to lesions in the oscillatory shear stress region.
Transglutaminase inhibition leads to a pronounced reduction in
macrophage accumulation in lesions that developed in the oscil-
latory shear stress region, but did not affect macrophage content in
the low shear stress area.
The relative amount of smooth muscle cells in the lesions in the
lowshear stress regiondid not signiﬁcantly differ from lesions in the
oscillatory shear stress region (Fig. 5E andF). Therewas alsonoeffect
on smooth muscle content in the low shear stress area with trans-
glutaminase inhibition. However, inhibition of transglutaminase
resulted in increased smooth muscle cell content in lesions in the
oscillatory shear stress region compared to control.As we observed such a profound effect of transglutaminase
inhibition on smooth muscle content in the oscillatory shear stress
region, we further explored the effect of transglutaminase inhibi-
tion on cultured smooth muscle cells. This showed that opposite to
the in vivo model, transglutaminase inhibition decreased smooth
muscle proliferation in vitro (Supplemental Fig. 3A). As an increase
in lesion smooth muscle content also could be a result of migration
from the media, we also tested the effect of transglutaminase
inhibition on smooth muscle migration in vitro. However, we
observed that transglutaminase inhibition did not affect smooth
muscle migration in a scratch wound assay (Supplemental Fig. 3B).
4. Discussion
The preferential localization of atherosclerotic lesions to areas of
disturbed shear stress is well documented [1,17]. The involved
sequence of events is not fully elucidated but includes locally
increased oxidative stress, induction of a more pro-inﬂammatory
and pro-coagulant endothelial phenotype [2], followed by inﬁltra-
tion of leukocytes and lipid uptake by macrophages. The impor-
tance of the current study is that it provides evidence that
endothelial TGM2 is a key element in the initial events leading to
disturbed shear-induced atherosclerosis. Thus, we established that
TGM2 shows a relatively high activity during oscillatory shear
stress in vitro and affects the expression of the chemotactic protein
MCP-1. We then showed that after onset of oscillating ﬂow in vivo
in carotid arteries, far less monocytes bind to endothelial cells in
TGM2 KO versus WT mice. Finally, chronic transglutaminase inhi-
bition had major effects on the size and nature of atherosclerotic
plaques at oscillating ﬂow spots, rendering them larger but with
a much lower macrophage and fat content. This spectrum of TGM2
effects was not observed under low laminar ﬂow, pointing towards
the involvement of TGM2 in atherogenesis in speciﬁcally oscillatory
ﬂow regions.
We considered that TGM2 expression could be regulated by
shear stress, and found that both laminar ﬂow and oscillatory ﬂow
decreased TGM2 mRNA and protein levels. Thus, the increase in
transglutaminase activity with oscillatory shear stress appears to
be regulated entirely at the posttranslational level. A key regulator
of transglutaminase activity in this respect may be nitric oxide
(NO). High laminar shear stress is well known to stimulate NO
release, whereas there is substantial evidence for ROS production
under oscillating ﬂow [18]. TGM2 is inactivated by NO through
nitrosylation of thiol groups [19] which has recently been shown to
be relevant for endothelial cell function [20,21] and small artery
remodeling [22]. Thus, shear-induced NO release could inactivate
TGM2 under healthy physiological conditions. In a situation of
increased ROS production, NO could be quenched by ROS and
thereby lead to activation of TGM2. A second possible link between
ROS and TGM2 is an increase in intracellular calcium to concen-
trations that could enhance TGM2 activity [23]. While ROS-induced
TGM2 activation is conceivable on the basis of such pathways,
further research is needed to identify the exact mechanism. Shear
stress was also shown to affect TGM2 secretion from endothelial
cells [20], but whether this plays a role in the expression of MCP-1
and transendothelial migration of monocytes remains to be
established.
We found that transglutaminase inhibition reduced the
expression of MCP-1 under oscillatory shear stress. MCP-1 is
upregulated in the in vivo cast model both in the area proximal to
the cast as well as the area distal to the cast [24]. It is therefore
unclear if endothelial MCP-1 expression is affected by trans-
glutaminase inhibition only in the area exposed to oscillatory shear.
Interestingly, a recent study using the currently used ﬂow-
modifying cast showed a preferential activation of NF-kB in
Fig. 5. Transglutaminase inhibition selectively affects lesion composition under oscillatory shear stress A) Oil Red O staining for lipids in lesions in the low and oscillatory shear
stress regions for control mice (n ¼ 8) and mice receiving the transglutaminase inhibitor (n ¼ 8). B) Quantiﬁcation of lipid accumulation by Oil Red O staining. Data are shown as
fraction of the intima area. C) CD68 staining to detect macrophages D) Quantiﬁcation of CD68 positive area. E) Smooth muscle actin staining (1A4). F) Area positive for 1A4 as
fraction of the intima area. Scale bar ¼ 150 mm. *Indicates p < 0.05; **Indicates p < 0.01. N.s. ¼ not signiﬁcant.
H.L. Matlung et al. / Atherosclerosis 224 (2012) 355e362360endothelial cells in the area distal to the cast, as compared to the
area proximal to cast [25]. Work from several groups showed that
TGM2 is essential in the prolonged activation of the transcription
factor NF-kB in various cell types [26e28]. Whether TGM2 could act
similarly in endothelial cells is currently unknown, but this would
provide an attractive possible mechanism to explain the selective
impact of transglutaminase inhibition during oscillatory shear. Onthe other hand, we found no changes in expression of three other
tested NF-kB targets, the adhesion molecules E-selectin, ICAM-1,
and VCAM-1. Future work is therefore needed addressing the
mechanisms of TGM2-dependent MCP-1 activation in detail.
Transglutaminase inhibition profoundly changed the plaque
phenotype in the oscillating ﬂow region. The strong reduction in
macrophage content is consistent with our ﬁnding that in TGM2 KO
H.L. Matlung et al. / Atherosclerosis 224 (2012) 355e362 361mice, far lessmonocytes/macrophagesbind to the endotheliumin the
ﬁrst 48 h after onset of oscillating ﬂow. The large reduction in lipid
content is likely to be secondary to the impaired macrophage accu-
mulation, since macrophages are responsible for most of the lipid
uptake. An unexpected ﬁnding was that lesion size and SMC content
were increased following transglutaminase inhibition. Additional
experiments showed that transglutaminase inhibition did not affect
smooth muscle migration in vitro, and actually decreased prolifera-
tion in vitro (Supplemental Fig. 3). The increase in smooth muscle
content in vivo therefore appears a paradoxical result. However, this
may also be an indirect consequence of decreased macrophage
content, as several groups showed that activated monocytes/macro-
phages can induce smooth muscle apoptosis [29,30]. Thus, TGM2
inhibition could indirectly, through a reduction in macrophage
content, increase smooth muscle survival.
The role of transglutaminases in atherosclerosis has been
addressed before, but not in the context of disturbed ﬂow. In
a previous study we observed a reduction in macrophage content
after transglutaminase inhibition in a model of femoral artery injury,
induced by a non-restrictive perivascular cuff without changes in
shear stress [13]. It thus seems that transglutaminases are activated in
that model because of the injury. ApoE//TGM2/ cross-bred mice
were reported to have a decrease in lesion size, ﬁbrosis and an
increase in lesionmacrophage content in one study [31], while others
only found a mild reduction in lesion fat content in these mice [32].
Possibly, apart fromdifferences in the anatomical locations thatwere
studied and the hemodynamic proﬁles that are associated with this,
the genetic background contributes to these apparently contradictory
results, as TGM2/mice from different originwere used [31,32].
In the present study we focused on transglutaminase activity in
endothelial cells and the subsequent implications for lesion
development and composition. However, monocytes/macrophages
are also known to express both TGM2 and the transglutaminase
FXIII. It has been reported that monocytes show an increase in
TGM2 expression upon attachment to the endothelium [33], which
suggests that this may play a role in transendothelial migration.
Thus, one could argue that in the current atherosclerosis model
a direct effect of the inhibitor on monocytes could contribute to the
results. However, this seems not very likely as the inhibitor was
applied systemically, while the effects on plaque progression were
only seen in the oscillatory shear stress region.
In conclusion, we showed that oscillatory shear stress increases
endothelial transglutaminase activity as compared to laminar shear
stress (7 dynes/cm2). Inhibition of transglutaminase activity
reduces MCP-1 expression in vitro. In vivo, TGM2 knockout mice
show reduced monocyte/macrophage recruitment to sites of
oscillatory shear stress. Inhibition of transglutaminase activity
in vivo reduced both macrophage content and lipid content in
plaques that developed in an oscillatory shear stress region. An
adverse effect of the transglutaminase inhibitor however, was the
increase in lesion size in this region. This was associated with an
increase in the area occupied by smooth muscle cells. Taken
together, these effects point out a beneﬁcial effect of trans-
glutaminase inhibition with respect to plaque composition in
regions exposed to oscillatory shear stress.Conﬂict of interest
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